Shares of Johnson & Johnson /zigman2/quotes/201724570/composite JNJ +1.04% were up 0.9% in trading on Monday, as the company nears the anticipated disclosure of interim results from a late-stage clinical trial evaluating its single-dose COVID-19 vaccine candidate. J&J said in mid-December it expects to share findings from the Phase 3 trial by the end of January, which would it the third company testing coronavirus vaccines in the U.S. to announce results from a closely watched Phase 3 trial. The other two vaccines, developed by BioNTech SE /zigman2/quotes/214419716/composite BNTX +6.45% /Pfizer Inc. /zigman2/quotes/202877789/composite PFE +1.21% and Moderna Inc. /zigman2/quotes/205619834/composite MRNA -4.03% , are both mRNA-based vaccines that received emergency use authorization from the Food and Drug Administration in December. J&J said in December that it will file for emergency authorization for its experimental adenovirus-based vaccine in February if results are ready by the end of January. The company is expected to release its fourth-quarter and full-year earnings on Tuesday. J&J's stock has gained 10.9% over the past year, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.67% is up 15.6%.